Search results
Pfizer cervical cancer drug gets full approval
Becker’s Hospital Review· 5 days agoThe FDA has granted full approval for Pfizer's Tivdak (tisotumab vedotin-tftv) to treat cervical cancer in patients whose disease has ...
Pfizer Stock Is Near An 11-Year Low — But Is It A Buy On This 'Massive' Upside?
Investor's Business Daily· 6 days agoAt the midpoints, earnings would climb more than 22% as sales rise almost 3%. Pfizer Stock And...
Labcorp gains FDA approval for hemophilia B diagnostic test By Investing.com
Investing.com· 6 days agoLabcorp (NYSE: LH) has announced the FDA approval of its nAbCyte Anti-AAVRh74var HB-FE Assay, a...
Pfizer (PFE) Q1 2024 Earnings Call Transcript
Motley Fool via Yahoo Finance· 6 days agoWe recently received the first U.S. FDA gene therapy approval for Pfizer with FDA approval for ...
Pfizer Inc (PFE) Q1 2024 Earnings Call Transcript Highlights: Navigating Post-COVID Challenges ...
GuruFocus.com via Yahoo Finance· 6 days agoThe company's oncology revenues grew 19% operationally over the same quarter a year ago, driven by successful acquisitions and product launches. Pfizer Inc (NYSE:PFE) received ...
Pfizer’s first-quarter results top estimates, while drugmaker boosts full-year profit outlook
Market Watch· 6 days agoAn expected drop in COVID-19-related product sales, including antiviral Paxlovid and vaccine...
Pfizer (PFE) Q1 Earnings & Sales Top, EPS Guidance Raised
Zacks via Yahoo Finance· 6 days agoIn the past year, Pfizer’s stock has declined 34.7% against an increase of 18.0% for the industry....
FDA approves Alecensa as leading-edge adjuvant therapy for ALK-positive lung cancer
Clinical Trials Arena via Yahoo Finance· 5 days agoThe approval, based on compelling results from the Phase III ALINA trial (NCT03456076...stage...
Pharma Stock Roundup: LLY, NVO, PFE Q1 Results, JNJ's New Plan to Resolve Talc Claims
Zacks via Yahoo Finance· 4 days agoFDA Approves Pfizer’s Hemophilia Gene Therapy: The FDA granted approval to Pfizer’s gene therapy ...
The top pharmaceutical companies by R&D expenditure
Pharmaceutical Technology via Yahoo Finance· 6 days agoMore regulatory milestones have already occurred in 2024 with the FDA’s approval of Daiichi Sankyo and AstraZeneca’s ADC, Enhertu (trastuzumab deruxtecan...
